RBI RESP
Alternative Names: RBI-RESPLatest Information Update: 07 Nov 2025
At a glance
- Originator Replicate Bioscience
- Class Influenza virus vaccines; Pneumococcal vaccines; Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 20 Oct 2025 Preclinical trials in Metapneumovirus infections (Prevention) in USA (unspecified route) (Replicate Bioscience pipeline, October 2025)
- 20 Oct 2025 Preclinical trials in Parainfluenza virus infections (Prevention) in USA (unspecified route) (Replicate Bioscience pipeline, October 2025)
- 20 Oct 2025 Preclinical trials in Respiratory syncytial virus infections (Prevention) in USA (unspecified route) (Replicate Bioscience pipeline, October 2025)